Relapsed Multiple Myeloma Clinical Trials

36 clinical trials for Relapsed Multiple Myeloma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager — RECRUITING · PHASE4
• Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers — RECRUITING · PHASE1
• A clinical trial of NOX-A12 in patients with mutiple myeloma who have previously been treated and who will be receiving bortezomib and dexamethasone treatment. — COMPLETED · PHASE2
• A study to evaluate the safety and efficacy of study drug radium-223 dichloride when given in combination with bortezomib and dexamethasone in patients with multiple myeloma that has recurred — COMPLETED · PHASE2
• INfections in Patients Treated With CAR-T — NOT_YET_RECRUITING
• Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide — ACTIVE_NOT_RECRUITING · PHASE1
• Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel study) — TERMINATED · PHASE2
• First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) — COMPLETED · PHASE1
• Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. — COMPLETED · PHASE2
• Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma — TERMINATED · PHASE1
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep — COMPLETED · PHASE2
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. — COMPLETED · PHASE3
• A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) — ACTIVE_NOT_RECRUITING · PHASE2
• MELFLUFEN FOR ELDERLY MYELOMA PATIENTS IN SECOND OR SUBSEQUENT RELAPSE (MELISSA) — OTHER · PHASE2
• A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma — COMPLETED · PHASE1
• A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma — COMPLETED · PHASE1
• Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma — TERMINATED · PHASE2
• Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma — TERMINATED · PHASE3
• A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma — COMPLETED · PHASE3
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma — COMPLETED · PHASE3
• Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma — WITHDRAWN · PHASE2
• Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma — WITHDRAWN · PHASE2
• Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use — COMPLETED
• Non-interventional Study on Salvage Auto in Relapsed Myeloma — COMPLETED
• Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma — COMPLETED · PHASE1
• Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) — OTHER · PHASE1
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma — COMPLETED · PHASE1
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease — COMPLETED · PHASE1
• ATRA, Celecoxib, and Itraconazole as Maintenance — COMPLETED · PHASE1
• Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma — COMPLETED · PHASE1
• Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia — COMPLETED · PHASE1
• A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma — COMPLETED · PHASE2

Refine this search